S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Alzchem Group Selects Bushy Park for New U.S. Chemical Facility

The German-based specialty chemicals manufacturer Alzchem Group AG has selected the 1,530-acre Bushy Park industrial site in Berkeley County, South Carolina, for a new U.S. production facility. The project aims to bolster domestic output of nitroguanidine, responding to consistent demand within global industrial markets.

Alzchem Group Selects Bushy Park for New U.S. Chemical Facility
Photo: Bio & News

The choice follows a rigorous site selection process, prioritizing Bushy Park’s established infrastructure and its logistical proximity to the Port of Charleston. As a subsidiary of Greenville-based Pacolet Milliken, the campus offers integrated utility systems and multimodal transportation access required for complex chemical operations. William Crawford, CEO and President of Pacolet Milliken, noted that the site’s existing framework provides an ideal foundation for companies seeking to strengthen their U.S. supply chain resilience.

Beyond physical infrastructure, the expansion leverages the Charleston region’s specialized labor pool in chemical processing. The project, supported by a partnership with Berkeley County and the State of South Carolina, is currently transitioning into the Front-End Engineering and Design phase. Construction is slated to commence in 2027, marking a significant addition to the site, which currently hosts ten industrial tenants and roughly 1,200 employees.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!